Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algorithm-Based Hydroxyurea Dosing in Sickle Cell Disease
NCT02225132Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea in sickle cell disease (SCD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Fetal Hemoglobin Level at 12 months. Started Aug 2014; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02225132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225132.